Trial Profile
Efficacy and Safety of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 13 Mar 2018 New trial record
- 01 May 2017 End point (Annual relapse rate) has been met, according to results published in the Pediatric Neurology.